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Figure　16．　Plasma　cortisol　levels董bllowing　the　administration　ofmedeto皿idine（MEDμg／kg）
and　rnidazolam（MID　mg／kg）in　cats（A）．　Each　point　and　vertical　bar　represent　the　mean　and
SEM（η＝5）．　The　AUC（0－6h）data　of　the　plaslna　glucose　graphs　are　plo枕ed　fbr　the　each
加atment（B）．　Colu㎜s　show　the　mean　w云th　ve牡ical　bars　indicating　SEM（刀＝5）．
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Trea㎞ents
MEiD80MED40－MlDO．5
Figure　17．　Plasma　NEFA　levels　fbllowing　the　administration　of　medetomidine（MEDμg／kg）
and　midazolam（MID　mg乃（g）in　cats（A）．　Each　point　and　vertical　bar　represent　the　mean　and
SEM（η＝5）．　a：significantly　diffbrent丘om　the　ini6al　value（P＜0．05）．　The　AUC（0－4h）
data　ofthe　plasma　glucose　graphs　aぎe　plotted　fbr　the　each　trea㎞ent（B）．　Columns　show　the
mean　with　vertical　b飢s　indicating　SEM（刀＝5）．＊：significantly　different　ffom　the　contro1（P
〈0．0玉）．
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Figure　18．　Plasma　norepinephrine　levels　fbUowing　the　administration　of　medetomidine
（MEDμg／kg）and　midazolam（MID　mg／kg）in　cats（A）。　Each　point　and　vertical　bar　repres斑t
the　mean　and　SEM（η＝5）。　a：signi五cantly　dif允rent伽m　the　i㎡tial　value（P＜0．05）．　The
AUC（0・・3h）data　of　the　plasma　glucose　graphs　are　plotted　fbr　the　each　treatment（B）．
Colu㎜s　show　the　mean　with　vertical　bars　indicating　SEM（η＝5）．＊，＊＊：signi負cantly
dif琵rent　f｝om　the　MIDO、5（P＜0．05，0．01）．
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Figure　19、　Plasma　epinephrine　levels　fbllowing　the　administration　of　medetomidine（MED
μg／kg）and　midazolam（MID　mglkg）in　cats（A）．　Each　point　and　veracal　baエrepresent　the
mean　and　SEM（η＝5）．　The　AUC（0－6h）data　of　the　plasma　glucose　graphs雛e　plotted　fbr
the　each　treatment（B）．　C◎1u㎜s　show　the　me狙軸vertical　b訂s　indicating　SEM（η＝5）．
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　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Discussion
　　　　The　present　study　revealed　that　midazolam　in　combination　with　medetomidine
sig垣丘c孤tly　prolonged出e　d砒atlon　of　l頒eral　rec㎜bency　induced　by　medetomidine　in　cats．
Furthermore，　the　addition　of　midazolam　to　medetomid輌ne　reduced　or　did　not　enhance　the
adverse　effbcts　such　as　hypothermia，　bradyarrhythmia，　and　bradypenia　induced　by
medetomid血e瓠one．　There允re，　in　spite　ofe趣cem斑t　of　the　i㎜ob晦d田ation，　the
combination　of　medetomid血e　and　midazolam　does　not　largely　alter　or　partially　diminish　the
medetomidille－mduced　adverse　effect∬elated　to　physical　parameters　measured　in　this　study．
　　　　Aprevious　study　has　revealed　that　medetomidine　induces　hyperglycemia　in　cats［58］．
This　is　one　of　the　undesirable　effects　fbr　the　use　of　medetomidine　in　feline　practice．　The
hyperglycemia　induced　by　medetomidine　is　accompanied　by　hyp◎sinsulinemia　similar　to　the
diabetes　meUitus．　This　hyperglycemic　effect　may　limit　the　use　of　medetomidine　in　cats　with
metabolic　and　neurohormonal　problems　such　as　diabetes　mellitus，　ketosis，　a且d　glycosuria．
Then，　it　was　examined　whether　medetomidine－midazolaln　combination　could　i㎡1uence　the
hyperglycemic　effヒct◎f　medetomidine．　The　present　study　revealed　that
medetomidine－midazolam　combinatioll　tended　to　induce　hyperglycemia，　but　not　significantly，
whereas　either　MED400r　MED80　irLduced　apparent　hyperglycemia．　On　the　other　hand，　in　the
present　experiment，　MIDO．5　alone　did　not　produce　a　significant　change　of　plasma　glucose
concentration　ill　cats．　These　results　indicated　that　MED40－MIDO。5　combination　can　reduce
the　hyperglycernic　effbct　induced　by　the　same　dose　of　1エ1edetomidme　alone．　This　effbct　of
midazolam　in　combination　with　medetomidine　may　be　due　to　interactions　between　the
α2－adrenoceptors　and　b飽zodiazepme　receptors　or　gamma－aminobu敏ric　acid（GABA）
receptors　on　the　neurohormonal　mechanismsτelated　to　hyperglycemia　and　hypoinsulinelnia．
However，　the　precise　mechanism　of　this　effect　is　u㎡mown．　This　effect　of
medetomidine－midazolam　combination　on　hyperglycemia　was　also　reported　in　laboratory
pigs［25］．　To　authoゴs㎞owledge，面s　is　the血st　report　that　medetomidine－midazolam
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combination　can　reduce　the　increase　in　blood　glucose　levels　induced　by　medetomidine　alone
mcats．
　　　　垣dlis　study，　the　decrease　ofplasma　insulin　concentrati皿was　not　s輌gnificantly　different
between　MED40－MIDO．5　and　MID40．　However，　recovery　f錐om　hypoinsulinemia　induced　by
MED40－MIDO．5　tended　to　be　more　rapid　conlpared　to　MED40　alone．　There　are　controversal
reports　on　the　effect　of　midazolam　alone　fbr　insulin　secretion　f士om　islet　cells．　Desborough　et
al［74］have　reported　that　the　use　of　midazolam　was　associated　with　a　decrease　in　insulin
secretion　during　upPer　abdominal　surgery，　and　a　decrease　in　blood　glucose　levels　in　humans．
Desborough　et　al［75］also　reported　that　midazolam　did　not　directly　i血ibit
glucose－stimulated　insulin　secretion　f士om　an∫ηv∫かo　rat　islet　preparation．　In　contrast，
Cuparencu［76］reported　that　midazolam　increased　plasma　insulin　leve1㎞
streptozotocin－induced　diabetes　in　rats．　In　present　pτesent　study，　the　midazolam　alone　did　not
significantly　affbct　plasma　insu夏in　concentration　in　cats．　On　the　other　han4　an　enha鳳cement
of　the　binding　of　GABA　to　low　a伍ni巧receptor　sites　may　give　rise　to　maエ1y　of　the仇v∫vo
actions　of　the　benzodiazepines［77］．　GABA　was　also　reported　to　inhibit　insulin　secretion
食omβcells　at　high　concentrations　of　glucose［78，79］，　and　inhibit　the　release　of　glucagon
丘omαcells［80］．　These　actions　may　also　i㎡1uence　on　the　plasma　glucose　levels　of　cats　giv斑
medetomidine－midazolam　combination．　The　present　resuhs　also　i皿dicated　that　the　changes　of
glucagon　levels　induced　by　MED40－MIDO．5　did　not　dif允r丘om　those　by　MED40　alone．　In
addition，　no　sigr匝cant　differences　in　glucose　levels　were　fbund　between　MIDO5　and　con仕ol
groups．　Therefbre，　it　seemed　that　the　do　se　of　midazolam　used　in　this　study　did　not　affect　the
P玉asma　ghcagon　and　insulin　levels，
　　　　Medetomidine　and　xylazine　have　been　reported　to　inhibit　norepinephrine　release　in
either　cats［61］or　dogs［9］．　The　present　results　that　MED40　and　MED80　inhibited　plasma
norepinephrine　release　were　in　agreem頭t　with　a　previous　result　in　cats［61］．
Medetomidine－midazolam　combination　tended　to　reduce　the　medetomidine－induced
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inhibition　of　no玄ep輌nephrme　release．　This　might　be　in　part　due　to伍e　effect　of皿i（lazolam　on
norepinephrine　release，　because　midazolam　alone　hlcreased　plasma　norepineph∫ine　levels．　In
contrast，　it　was　reported　that　midazolam　did　not　significantly　change　plasma　norepinephrine
concentrations　in　humans［81］．1加his　study，　however，　it　is　un㎞own　whether　this　increase　in
norepinephrine　concentration　was　induced　by　phamlacological　ef琵ct　ofmidazolam，　or　by
excitement－1ike　behavior　associated　with　midazolam　administration．　This　is　the飯st　report
that　midazolam　increased　plasma　norepinephrine　concentration　in　cats
　　　　Medetomidine，　midazolam，　and　the　combination　of　both（kugs　did　not　sigl面cantly
change血e　plasma　epinephrine　conce迫tration　of　cats　in面s　s加dy．　T｝1e　resu玉t　as　to　the　ef琵ct
of　midazolarn　was　in　agreement　with　a　previous　report　in　humans［81｝On　the　other　hand，
several　studies　reported　that　medetomidineτeduced　the　plasma　epinephrine　concentration　in
cats［61］and　dogs［9］．　However，　medetomidine　has　been　also　reported　not　to　affbct皿the
epinephrine　level　in　humans［82］．　Thus，　the　effect　of　medetomidine　oll　the　plasma
epmephri館concentration　was　controversia正．
　　　　In　this　study，　there　were　no　significant　changes　ofplasma　cortisol　concentration　in　all　of
groups．　The　present　results　were　similar　to　previous　findings［61］．　No　significant　differences
were　also貴）und　among　the　MED40，　MED80，　and　MED40－MIDO．5　groups．　Therefbre，　these
results　indicated　that　the　addition　ofmidazolam　does　not　a銑ct　the　plasma　cortisol
concentration　of　cats　given　lnedetornidine．
　　　　Plasma　NEFA　concentration　has　been　reported　to　be　reduced　by　medeto皿idine　in　cats
［61］．This　response　may　be　due　to　the　suppression　oflipolysis　mediated　byα2－adrenoceptors
［57，58］．The　results　of　this　s加dy　confirmed　a　previous　report　in　which　medetomidine
decreased　plasma　NEFA　levels［61］．　On　the　other　hand，　the　changes　ofplasma　NEFA
concen仕ations　in　MED40－MIDO．5　combination　were　similar　to　those　in　MED40　alone　in　this
study．　Therefbre，　the　present　results　indicated　that　the　addition　ofmidazolam　does　not　alter
the　inhibition　of　lipolysis　induced　by　lnedetomidine　in　cats．
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　　　　In　conclusion，　Medetomidine－midazolam　combinati皿reduced重he　hyperglycemia
induced　by　medetomidine　in　cats．　The　decrease　ofplasma　norepinephrine　levels　induced　by
medetomidine　alone　was　diminished　by　the　addition　of　midazolam．　Midazolam　alone
increased　plasma　norepineph地e　Ievels，　but　did　not　change　glucose，　msulin，　glucagon，
cortiso1，　epinephrme，　and　NEFA　concentrations　in．　cats．　Therefbre，　this　study　revealed　that
medetomidine－midazolaln　combination　produces　mi㎡mal　neuroho㎜onal　and　metabolic
changes　without　greater　adverse　effbcts　when　compared　to　medetomidine　alone　in　healthy
cats．
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Chapter　4
General　conclusion
　　　　In　cats，　both　medetomidine　and　xylazine　included　remarkable　hyperglycemia．　It　was
greater　in　cats　than　dogs　reported　previously．　It　was　fb㎜d　that　hyperglycemia　at　early　phase
（Oto　2　hours　after　administration）in　the　medetomidine　treated　group　was　not　dose－dependent．
On　the　other　hand，　xylazine　induced　dose－dependem　hyperglycemia　th玄ough　the　experiments．
The　changes　of　insulin　concentration　did　not　show　significant　dose－dependency　in　either
medetomidine　or　xylazine　treated　group．　These　results　suggested　the　differences　on　the
mech・・i・m・fhyp・・glycemi・b・衙een　m・d・t・mid血e　and　xylazi・・，・1血・ugh　b・th
medetomidine　and　xylazine　wereα2－adrenoceptcr　agollists．　The　diffεrences　on　the　affinity　to
each　subtype　ofα一adrenoceptors　between　medetomidine　and　xylazine，　and／or　the　affinity　to
the　imidazoline　receptor　ofmedetomidine　may　contrib磁e　to　differences　on　the　mechanism　of
hyperglycemia．　However，　the　present　study　could　not　reveal　the　precise　mechanism．
　　　　Either　medeto㎡dine　or　xylazine　decreased　the　concentration　of　norepinephrine．　Higher
dose　of　medetomidine（160，320μg／kg）significantly　decreased　the　concentration　of
norepinephr輌ne．「While，　xylazi皿e　tended　to　decrease　the　plasma　norepinephrine　concentration，
but　not　significantly．　Plasma　NEFA　concentrat輌on　was　also　significantly　decreased　in　both
the　medetomidine　and　xylazine　treated　groups．　These　results　agree　with　a　previous　report　in
dogs．
　　　　In　chapter　2，　it　was　demonstrated　that　midazolam　m　the　combination　with　medetolnidine
suppressed　the　hyperglycem輌a　induced　by　medetomidine　alone　in　cats．　The　combination　of
皿edetomidille　and　midazolam　accelerated　the　recovery　of　insulin　concentration　compared　to
medetomidine　alone．　On　the　other　hand，　rnidazolam　alone　did　not　affbct　the　plasma
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concentrations　of　both　glucose　and　insulin．　Therefbre，　only　wh頭midazolam　was
administered　in　the　combination　with　medetolnidine，　suppressed　medetomidine－induced
hyperglycemia　was　suppressed．　The　interactions　among　theα2－adrenoceptors，　imidazoline
receptors，　benzodiazepine　receptors，　and　GABA　receptors　may　be　involved　in　these
responses．　However，　the　present　study　and　any　other　reports　did　not　reveal　detailed
mechanisms　on　the　interactions　ofmedetornidine　and　midazolam　fbr　hyperglycemic　effect．
　　　　Plasma　c皿centration　of　norepinephrine　was　decreased　by　medetomi垣ne　administration．
The　addition　of　midazolam　suppressed　the　decrease　of　norepmephrine　concen仕ation　induced
by　medetomidine．　It　may　due　to　the　effect　of　midazolam　because　midazolam　alone　increased
Plasma　norepinephrine　concentration．
　　　　In　conclusion，　the　present　study　revealed　that　medetolnidine　unlike　xylazine　did　not
induce　dose－dependellt　hyperglycemia　at　early　phase　in　cats．　Such　hyperglycemia　was　greater
in　cats　than　dogs　reporte（1　previously．　This　s加dy　revealed　that　midazolam　in　combination
with　medeto㎡dille　suppress　the　hyperglycemia　induced　by　medetomidine　alone　m　cats．
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Summary
　　　　In　chapter　1，　the　ef丘cts　ofxy1泣ine　and　medetomidine　on　some　ofne田oho㎜onal　and
metabolic　variables　were　investigated　and　compared　in　healthy　cats．　Five　cats　were　used
repeatedly　in　each　of　l　l　groups，　which　were　treated　with　the　physio1◎gical　saline　solution
（contro1），0．5，1，2，4，　alld　8　mg！優（g　xylazine，　and　20，40，80，160，　and　320μg／kg
medetomidine　in仕amuscularly．　Blood　samples　were　takell　fbr　10times　during　24　h丘om　the
jugular　vein、　Plasma　glucose，　insulk」cortisol，　epinephrine，　norepinephrine，　glucagon，　and
nonesterified　fatty　acid　concentrations　were　dete㎜ined．　Both　xyla亘ne　and　medetomidine
induced　remarkable　hyperglycemia　in　a　dose－dependent　ma皿er，　but　the　hyperglycernic
response　of　medetomidine丘om　O　to　3　h　was　not　dose－dependent．　Both　xy玉azine　and
medetomidme　suppressed　epinephrine　and　norepinephrine　release．　In　bo也xylazine　and
medetomidine　groups，　the　suppression　of　catecholamine　release　was　not　dose－dependent　at
the　tested　dosages．　Both　agents　inhibited　insulin　release　and　lipolysis　with　similar　potency，
and　tended　to　suppress　cortisol　release．　The　glucagon　levels　did　not　change　sig垣負cantly　in
any　of　groups．　These　results　suggested　that　the　effects　of　1孤e（ietomidine　and　xylazine　on
glucose　metabolism　and　catecholamine∫elease　may　not　be　due　only　to　the　actions　mediated
byα2－adrenocepto壬s．
　　　In　chapter　2，　the　e£飴cts　ofmedetomidine・・midazolam　combination　on　some
neurohoτmonal　and　metabolic　vaぎiables　were　investigated　in　healthy　cats．　Five　cats　were　used
repeatedly　in　each　of　5　groups，　wh輌ch　were　tτeated　with　physiolog三cal　saline　so夏ut輌on
（contro1），0、5　mg／kg　midazolam，40μg／kg　medetomidine，80μg／kg　medetomidine，　and　40
μg／kg　medetomidine　and　O　5　mg／kg　midazolam　in伎amuscularly．　Blood　samples　were　taken
振）r10times　dufmg　24　h　f｝om　the　catheter　in仕oduced　into　the　j　uglar　vein．　Plasma　glucose，
insulin，　glucagol1，　co∫tisol，　n皿esterified　fatty　acid（NEFA），　norepinephrille，　and　epinephrine
concentrations　were　detemlned．　Addit元onaUy，　duration　of　Iateral　recumbency，　recta1
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temperature，　heart　and　respiration　rates　were　exan亘ned．　The　combination　of　medetomidine
and　midazolam　enhanced　the　duration　of　lateral　rec㎜bency　and　reduced　the　hyperg▲ycemia
induced　by　rnedetolnidine　alone．　Recovery丘om　hypoinsulinemia　induced　by
medetomidine－midazolam　combination　tended　to　be　more　rapid　compared　to　same　dose　of
lnedetomidine　alone．　The　decrease　of　plasma　norepinephrine　levels　induced　by血edetomidine
a1皿e　was　dimi垣shed　by　the　additio加f面dazolam　to　medetomidine．　Midazolam　alone　did
not　significantly　change　plasma　glucose，　insulin，　glucagon，　cortisol，　epinephrine，　and　NEFA
concentrations，　but　increased　norep輌nephr輌ne　concentration．　This　smdy　revealed　that　the
combination　ofmedetomidine　and　midazo　lam　produces　minimal　neurohormonal　and
metabolic　changes　when　compared　to　medetomidine　alone　in　cats．
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